Department of Pulmonary Medicine, Sendai Kousei Hospital, 4-15, Hirosemachi, Aoba-ku, Sendai, Miyagi, 980-0873, Japan.
Department of Respiratory Medicine, Tohoku Medical and Pharmaceutical University, 1-21-1, Fukumuro, Miyagino-ku, Sendai, Miyagi, 983-8512, Japan.
Int J Clin Oncol. 2018 Dec;23(6):1046-1051. doi: 10.1007/s10147-018-1304-5. Epub 2018 Jun 6.
Diarrhea post-antibiotic use is primarily attributed to Clostridium difficile infection (CDI)-induced mucosal lesions, and evidence of CDI in patients undergoing chemotherapy without prior antibiotic treatment is also increasing. However, few studies have investigated the relationship between chemotherapy use and diarrhea. This study aimed to determine whether the incidence of CDI increased in patients with lung cancer undergoing chemotherapy even without prior antibiotic treatment.
We conducted a retrospective study and investigated the presence of Clostridium difficile (C. difficile) and its toxins in patients who experience diarrhea during chemotherapy. If grade 2 or higher diarrhea was noted, a stool culture was performed to detect anaerobic organisms and C. difficile toxins A and B.
A total of 345 consecutive patients (492 in terms of chemotherapy regimens) were enrolled in the study. Grade 2 or higher diarrhea was observed in patients using 36 (7.3%) of these regimens, among which CDI without prior antibiotic exposure was confirmed in patients using 8 regimens (22.2%).
CDI may remain undetected in patients undergoing chemotherapy even in those who had not received antibiotic treatment previously, unless due attention is paid to its possibility. Testing for C. difficile toxins is highly recommended to expedite timely treatment for diarrhea in such patients. Further studies are needed to clarify the relationship between chemotherapy drug use and CDI to facilitate prevention.
抗生素使用后腹泻主要归因于艰难梭菌感染(CDI)引起的黏膜损伤,并且在没有先前抗生素治疗的情况下接受化疗的患者中 CDI 的证据也在增加。然而,很少有研究调查化疗使用与腹泻之间的关系。本研究旨在确定即使在没有先前抗生素治疗的情况下,接受化疗的肺癌患者中 CDI 的发病率是否增加。
我们进行了一项回顾性研究,调查了在化疗期间发生腹泻的患者中是否存在艰难梭菌(C. difficile)及其毒素。如果出现 2 级或更高级别的腹泻,则进行粪便培养以检测厌氧生物和 C. difficile 毒素 A 和 B。
共有 345 例连续患者(492 例化疗方案)入组研究。在使用这些方案中的 36 种方案(7.3%)的患者中观察到 2 级或更高级别的腹泻,其中在使用 8 种方案(22.2%)的患者中证实了没有先前抗生素暴露的 CDI。
除非特别注意到这种可能性,否则在接受化疗的患者中,即使先前未接受抗生素治疗,CDI 也可能未被检测到。强烈建议对艰难梭菌毒素进行检测,以加快对这些患者腹泻的及时治疗。需要进一步研究阐明化疗药物使用与 CDI 之间的关系,以促进预防。